Provided by Tiger Fintech (Singapore) Pte. Ltd.

3SBIO

20.200
+0.7603.91%
Volume:60.11M
Turnover:1.21B
Market Cap:48.46B
PE:21.45
High:20.850
Open:19.500
Low:19.260
Close:19.440
Loading ...

HK Movers | HK's Biotech Shares Soar. Asymchem up 15%; Laekna up 13%; Ascletis, CanSinoBIO up 9%

Tiger Newspress
·
21 May

Stock Track | 3SBIO Soars 5.32% on $6 Billion Licensing Deal with Pfizer for Cancer Drug

Stock Track
·
21 May

3SBio to Grant Pfizer Exclusive License for Anti-Cancer Injection

MT Newswires Live
·
20 May

Hong Kong Stocks Rise as China Cuts Interest Rates; CATL Jumps 16% in Debut

MT Newswires Live
·
20 May

GLOBAL MARKETS-Asian stocks inch higher, Aussie dips as RBA cuts rates

Reuters
·
20 May

China, HK stocks rise as rate cut boosts sentiment

Reuters
·
20 May

Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer

Dow Jones
·
20 May

Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion

Bloomberg
·
20 May

Shares of 3SBio up 40% After Licensing Deal With Pfizer

THOMSON REUTERS
·
20 May

BUZZ-HK-listed 3SBio hits 7-year peak on Pfizer licensing deal

Reuters
·
20 May

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

Reuters
·
20 May

Stock Track | 3SBIO Soars 14.90% on $6 Billion Licensing Deal with Pfizer for Cancer Drug

Stock Track
·
20 May

Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug

Reuters
·
20 May

Sunshine Guojian Says Co and Affiliates Have Granted Pfizer an Exclusive License on Commercialization of Cancer Drug

THOMSON REUTERS
·
20 May

BRIEF-Sunshine Guojian Says Co And Affiliates Have Granted Pfizer An Exclusive License On Commercialization Of Cancer Drug

Reuters
·
20 May

BRIEF-Pfizer Enters Into Exclusive Licensing Agreement With 3SBio

Reuters
·
20 May

Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707

Reuters
·
20 May

3SBio Inc. Enters Exclusive License Agreement with Pfizer for PD-1/VEGF Bispecific Antibody

Reuters
·
20 May

BRIEF-3Sbio Enters Into License Agreement With Pfizer

Reuters
·
20 May

3SBio - Entering Into License Agreement for Pd-1/Vegf Bispecific Antibody (Ssgj-707) With Pfizer

THOMSON REUTERS
·
20 May